Keyphrases
Antimicrobial Therapy
16%
Clinical Efficacy
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Disease-modifying Effect
16%
Exacerbation Rate
16%
Forced Expiratory Volume in 1 Second (FEV1)
33%
G551D
100%
G551D mutation
16%
Growth Quality
33%
Ivacaftor
100%
Long-term Benefit
16%
Long-term Disease
16%
Longitudinal Observational Study
16%
Lung Function Decline
16%
Lung Function Growth
16%
Prospective Longitudinal Study
16%
Pseudomonas Aeruginosa (P. aeruginosa)
16%
Pulmonary Exacerbation
16%
Quality of Life
16%
Quality of Life Assessment
16%
Sweat Chloride
33%
Medicine and Dentistry
Antimicrobial Therapy
16%
Cohort Analysis
16%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Diseases
16%
Forced Expiratory Volume
33%
Ivacaftor
100%
Lung
33%
Observational Study
16%
Pseudomonas aeruginosa
16%
Quality of Life
16%
Quality of Life Measure
16%
Sweat
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antimicrobial Therapy
16%
Cohort Study
16%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Diseases
16%
Ivacaftor
100%
Observational Study
16%
Pseudomonas aeruginosa
16%
Biochemistry, Genetics and Molecular Biology
Cohort Study
16%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Forced Expiratory Volume
33%
Ivacaftor
100%
Observational Study
16%
Pseudomonas aeruginosa
16%